Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Syndax Pharmaceuticals (SNDX) Assets Average (2016 - 2026)

Syndax Pharmaceuticals (SNDX) has disclosed Assets Average for 11 consecutive years, with $501.2 million as the latest value for Q1 2026.

  • For Q1 2026, Assets Average fell 26.59% year-over-year to $501.2 million; the TTM value through Mar 2026 reached $501.2 million, down 26.59%, while the annual FY2025 figure was $627.3 million, 6.22% down from the prior year.
  • Assets Average hit $501.2 million in Q1 2026 for Syndax Pharmaceuticals, down from $540.7 million in the prior quarter.
  • Across five years, Assets Average topped out at $682.8 million in Q1 2025 and bottomed at $383.1 million in Q3 2022.
  • Average Assets Average over 5 years is $502.3 million, with a median of $501.2 million recorded in 2026.
  • Year-over-year, Assets Average soared 52.68% in 2022 and then fell 26.59% in 2026.
  • Syndax Pharmaceuticals' Assets Average stood at $428.5 million in 2022, then grew by 18.11% to $506.1 million in 2023, then grew by 13.69% to $575.3 million in 2024, then fell by 6.01% to $540.7 million in 2025, then fell by 7.32% to $501.2 million in 2026.
  • According to Business Quant data, Assets Average over the past three periods came in at $501.2 million, $540.7 million, and $574.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.